Glenmark Pharmaceuticals is currently trading at Rs. 564.25, up by 13.55 points or 2.46% from its previous closing of Rs. 550.70 on the BSE.
The scrip opened at Rs. 555.00 and has touched a high and low of Rs. 566.20 and Rs. 554.00 respectively. So far 34839 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 930.00 on 11-May-2017 and a 52 week low of Rs. 517.40 on 19-Feb-2018.
Last one week high and low of the scrip stood at Rs. 553.00 and Rs. 537.50 respectively. The current market cap of the company is Rs. 15801.42 crore.
The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 37.07% and 16.40% respectively.
Glenmark Pharmaceuticals has presented new data on Ryaltris, an investigational fixed-dose combination nasal spray for Seasonal Allergic Rhinitis (SAR), at the AAAAI/WAO Joint Congress in Orlando, Florida.
New data was studied on more than 2,400 patients to 14 days of twice-daily treatment with Ryaltris or placebo. Ryaltris (mometasone furoate (25 mcg) and olopatadine hydrochloride (665 mcg)), formerly GSP 301 Nasal Spray, is Glenmark’s leading respiratory candidate with a New Drug Application filing anticipated in the first half of 2018.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
